<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019549</url>
  </required_header>
  <id_info>
    <org_study_id>15994</org_study_id>
    <secondary_id>I8D-MC-AZEB</secondary_id>
    <nct_id>NCT03019549</nct_id>
  </id_info>
  <brief_title>A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin</brief_title>
  <official_title>Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in Caucasian Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of lanabecestat on rosuvastatin. The
      amount of rosuvastatin in the blood will be compared, when taken alone, and then when taken
      with lanabecestat. The amount of lanabecestat that gets into the bloodstream will be
      measured. Information about any side effects that may occur will also be collected.

      Participants will be on study for 21 days with a follow-up at least 7 days afterwards.

      Screening will be undertaken within 45 days prior to enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2017</start_date>
  <completion_date type="Actual">May 22, 2017</completion_date>
  <primary_completion_date type="Actual">May 22, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under The Drug Concentration Time Curve (AUC) of Rosuvastatin</measure>
    <time_frame>Period 1: Predose of rosuvastation through 120 hours postdose. Period 2: Predose of rosuvastatin through 120 hours postdose</time_frame>
    <description>PK: AUC of Rosuvastatin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Drug Concentration Time Curve During a 24-hour Dosing Interval (AUCτ) of Lanabecestat</measure>
    <time_frame>Period 2: Day 7, predose of Lanabecestat through Day 9, predose of Lanabecestat</time_frame>
    <description>PK: AUCτ of Lanabecestat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of Lanabecestat</measure>
    <time_frame>Period 2: Day 7, predose of Lanabecestat through Day 9, predose of Lanabecestat</time_frame>
    <description>PK: Cmax of Lanabecestat</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin administered once orally on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanabecestat + Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 2: Lanabecestat administered orally for multiple days alone and one day in combination with rosuvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanabecestat</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Lanabecestat + Rosuvastatin</arm_group_label>
    <other_name>LY3314814</other_name>
    <other_name>AZD3293</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_label>Lanabecestat + Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women not of childbearing potential may participate and include those who are:

               -  Infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or
                  tubal ligation), congenital anomaly such as mullerian agenesis; or

               -  Postmenopausal - defined as women over 50 years of age with an intact uterus who
                  have not taken hormones or oral contraceptives within 1 year, who have had either
                  Spontaneous cessation of menses for at least 12 consecutive months, or 6 to 12
                  months of spontaneous amenorrhea with follicle-stimulating hormone level greater
                  than (&gt;)40 milli-international units per millilitre (mIU/mL) consistent with
                  menopause

          -  Caucasian and may be of Hispanic ethnicity

          -  Body mass index (BMI) of 19 to 32 kilogram per meter square (kg/m²), inclusive, at the
             time of screening

        Exclusion Criteria:

        - Have a clinically significant abnormal blood pressure or heart rate (supine) as
        determined by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2017</study_first_submitted>
  <study_first_submitted_qc>January 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

